Paranasal Sinus and Nasal Cavity Cancer: Causes, Symptoms and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cancers of the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal sinuses) and nasal cavity are uncommon malignancies, representing less than 1% of all human cancers and approximately 3% of head and neck malignancies. The maxillary sinus is the most commonly involved site, accounting for approximately 60% of sinonasal cancers. The ethmoid sinuses, nasal cavity proper, and frontal and sphenoid sinuses account for the remainder. Squamous cell carcinoma (SCC) represents approximately 60-70% of sinonasal malignancies; adenocarcinoma — particularly the intestinal-type adenocarcinoma strongly linked to occupational wood dust exposure — and sinonasal undifferentiated carcinoma (SNUC), olfactory neuroblastoma (esthesioneuroblastoma), and adenoid cystic carcinoma comprise most other subtypes. The disease predominantly affects males aged 50-70. Diagnostic delay is characteristic because early symptoms are indistinguishable from chronic sinusitis, resulting in most patients presenting at locally advanced stage with orbital or intracranial extension.

Occupational exposures are the dominant established risk factors for sinonasal malignancies, unlike most other head and neck cancers. Hardwood dust (oak, beech, furniture manufacture) is a known Group 1 IARC carcinogen for sinonasal adenocarcinoma, conferring a risk of approximately 40-fold in heavily exposed woodworkers. Leather dust from boot and shoe manufacture, nickel refining compounds, and chromium compounds are established risk factors for SCC. Formaldehyde exposure is associated with squamous pathology. HPV infection (predominantly HPV-16) contributes to a subset of sinonasal SCC in a manner analogous to oropharyngeal cancer, with better clinical outcomes in HPV-positive cases. Tobacco smoking increases general sinonasal cancer risk. Inverted sinonasal papilloma is an HPV-associated benign tumor with well-recognized malignant transformation potential to SCC, occurring in approximately 5-15% of cases. Thorotrast (radioactive contrast agent used historically) causes sinonasal malignancies decades after exposure.

Early sinonasal cancer produces symptoms virtually identical to chronic sinusitis, making early diagnosis extremely difficult. Key warning signs suggesting malignancy rather than benign sinus disease include: unilateral nasal obstruction that fails to respond to standard sinus treatment; unilateral epistaxis (nosebleed) without trauma; facial pain or pressure, particularly unilateral, worsening over weeks; cheek swelling or facial asymmetry; dental symptoms including toothache, loosening of upper teeth, or ill-fitting dentures from maxillary floor erosion; and persistent clear or bloody nasal discharge. As the tumor invades adjacent structures, additional manifestations develop: diplopia and proptosis from orbital invasion; trismus (limited mouth opening) from pterygoid plate invasion; facial numbness from infraorbital nerve involvement; and vision loss from optic nerve compression. Cervical lymphadenopathy indicates regional nodal spread in advanced disease, present at diagnosis in approximately 15-20% of sinonasal SCC cases.

Endoscopic nasal examination with biopsy of visible tumor provides initial tissue diagnosis and is performed under local or general anesthesia depending on tumor location and patient tolerance. CT of the paranasal sinuses with bone windows is essential for defining bony architecture, cortical destruction (floor of orbit, skull base, pterygoid plates, hard palate), and tumor extent. MRI with gadolinium provides superior soft tissue delineation, differentiates tumor from retained secretions, and defines perineural spread, dural involvement, and intracranial extension. PET/CT with 18F-FDG assesses regional nodal and distant metastatic disease, which is uncommon at presentation (approximately 5%). AJCC 8th edition TNM staging is applied, which differs by subsite (maxillary sinus versus nasal cavity/ethmoid sinus). HPV/p16 IHC testing is performed on all SCC specimens. Sinonasal undifferentiated carcinoma (SNUC) requires extensive IHC panel to exclude metastatic neuroendocrine or undifferentiated carcinoma from other sites.

Combined modality treatment with surgery followed by adjuvant radiotherapy is the established standard for most resectable sinonasal malignancies. Surgical approaches have evolved significantly: endoscopic endonasal skull base surgery (for selected tumors without broad orbital or dural invasion) provides equivalent oncological outcomes to open surgery with superior functional outcomes at high-volume centers. Open craniofacial resection (combining neurosurgical transcranial approach with ENT endonasal or lateral rhinotomy access) remains the standard for tumors with extensive cribriform plate or intracranial involvement. Orbital exenteration (removal of orbital contents) is required only when the orbital fat or extraocular muscles are invaded. Adjuvant intensity-modulated radiotherapy (IMRT) at 60-66 Gy targets the tumor bed and at-risk nodal regions. Concurrent cisplatin-based chemotherapy is added for unresectable disease, positive margins, or high-risk pathological features. Proton beam radiotherapy is preferred at expert centers for tumors immediately adjacent to optic nerves, brain, and brainstem to minimize late radiation toxicity. Olfactory neuroblastoma (esthesioneuroblastoma) follows specific Kadish staging and treatment algorithms.

The most actionable preventive measure is elimination or minimization of occupational hardwood and leather dust exposure through engineering controls, adequate respiratory protective equipment, and workplace hygiene standards. Workers in high-risk industries (woodworking, furniture manufacture, nickel refining, shoemaking) should have regular occupational health surveillance and be educated about early sinonasal cancer warning signs to promote prompt reporting of symptoms. HPV vaccination in adolescents may reduce the risk of HPV-driven sinonasal carcinoma. Tobacco cessation reduces general mucosal carcinogen exposure. No validated population screening program exists. Patients with known inverted sinonasal papilloma should undergo endoscopic surveillance with biopsy of any suspicious areas, as malignant transformation to SCC requires ongoing monitoring.

Any adult with unilateral nasal obstruction, nosebleeds, or facial pain that persists beyond 4-6 weeks despite appropriate sinus treatment — particularly if the symptoms are new, worsening, and on only one side — requires ENT referral with endoscopic nasal examination and cross-sectional imaging. Unilateral symptoms are the key clinical red flag that distinguishes concern for malignancy from ordinary sinusitis, which typically affects both sides. Facial or cheek swelling, upper tooth loosening, or changes in vision should prompt same-week specialist evaluation. Workers in high-risk occupational settings (woodworking, nickel refining) who develop any of these symptoms should have a low threshold for endoscopic evaluation. Any sinonasal mass or soft tissue lesion identified on head and neck CT or MRI performed for other reasons requires histological biopsy before treatment.

Maxillary sinus SCC overall 5-year survival: approximately 30-40%. Nasal cavity tumors have better prognosis (~60% 5-year survival). Advanced orbital or intracranial invasion significantly worsens outcomes. HPV-positive sinonasal SCC behaves more favorably than HPV-negative. Olfactory neuroblastoma: 5-year survival approximately 70-80% for Kadish Stage A/B. Early-stage disease treated with combined modality therapy achieves better cure rates. The prognosis for Paranasal Sinus and Nasal Cavity Cancer: Causes, Symptoms and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.